Vascular Changes After Intra-bleb Injection of Bevacizumab

Coote, Michael; Ruddle, Jonathan B; Qin, Queena; Crowston, Jonathan G

doi:10.1097/ijg.0b013e31815f5345

Cited by 40 publications

(31 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meanwhile, an increasing number of clinical case reports and observational case series described the potential beneficial effect of bevacizumab on glaucoma surgery outcome (Biteli and Prata, 2013;Coote et al, 2008;Kahook et al, 2006;Klos-Rola et al, 2013;Zarnowski and Tulidowicz-Bielak, 2011). A pilot study, performed with a small number of patients (12) to evaluate a single subconjunctival bevacizumab injection (1.25 mg; 50 ml), demonstrated that bevacizumab is a potential adjunctive treatment for reducing the incidence of bleb failure after trabeculectomy.…”

Section: Inhibition Of Vascular Endothelial Growth Factormentioning

confidence: 96%

Modulation of wound healing in glaucoma surgery

Velde¹,

Bergen²,

Vandewalle³

et al. 2015

Progress in Brain Research

View full text Add to dashboard Cite

Section: Inhibition Of Vascular Endothelial Growth Factormentioning

confidence: 96%

Modulation of wound healing in glaucoma surgery

Velde¹,

Bergen²,

Vandewalle³

et al. 2015

Progress in Brain Research

View full text Add to dashboard Cite

“…Coote 23 reported the use of subconjunctival bevacizumab in a patient who exhibited bleb vascularity after uncomplicated clear corneal phacoemulsification cataract surgery. Three months prior to cataract surgery, the patient had undergone a limbal based trabeculectomy with Mitomycin C. Two weeks after the injection of bevacizumab, the bleb was noted to be significantly less vascular and by 6 months the bleb was quiet, diffuse, and functioning at an IOP of 10 mmHg.…”

Section: Post-operative Use Of Bevacizumabmentioning

confidence: 99%

Angiogenesis: Trabeculectomy and Bevacizumab

Jue

2009

Seminars in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…M. Coote и J. Ruddle провели однократную инъекцию бевацизумаба в полость подушки на 10 дней после экстракции катарак-ты на глазах, перенёсших синустрабекулэктомию за 3 месяца до факоэмульсификации. В сроки до полугода они отмечали выраженное снижение степени васкуляризации ФП [11].…”

Section: применение ингибиторов Vegf после фистулизирующих антиглаукоunclassified

VEGF inhibitors in glaucoma surgery

Mamikonyan¹,

Petrov²,

Сафонова³

2016

Ophthalmology Reports

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a signaling protein, that controls vasculogenesis, angiogenesis, vascular support and stimulates permeability of small blood vessels. The following isoforms are presently known: VEGF-A, VEGF-B, VEGF-C, VEGF-В and PGF. VEGF-A, that regulates neoangiogenesis and fibroblast formation, is thought to play the most important role in human organism. Increased expression of VEGF may lead to development and aggravation of pathological conditions including oncology. The article presents a review of preclinical and clinical studies of the main VEGF-inhibitors - bevacizumab and ranibizumab, as well as a brief account on other existing medications of this group. It describes ophthalmological indications for the use of antiangiogenetic agents, as well as the ways of their possible off-label use. The review presents investigations of intravitreal and intracameral injections of VEGF-inhibitors in patients with retinal, chorioidal, iris, and anterior chamber angle neovascularization. It gives examples of successful anti-VEGF use before Ahmed glaucoma valve drainage device implantation and in cases of neovascular glaucoma, induced by radiation therapy for intraocular tumors. Tenon’s capsule’s fibroblasts take part in the process of postoperative wound healing and scarring. According to the latest research, this process could be modulated by angiogenesis inhibitors. This review also recounts the use of anti-angiogenic agents to inhibit postoperative fibroblast proliferation, when used as monotherapy, or as an adjuvant to mitomycin С or 5-fluorouracil. It reviews the research on VEGF-inibitors use in combination with postoperative needling.

show abstract

Vascular Changes After Intra-bleb Injection of Bevacizumab

Abstract: Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.

Cited by 40 publications

References 6 publications

Modulation of wound healing in glaucoma surgery

Modulation of wound healing in glaucoma surgery

Angiogenesis: Trabeculectomy and Bevacizumab

VEGF inhibitors in glaucoma surgery

Contact Info

Product

Resources

About